Related Experiment Video
Updated: Jan 12, 2026

09:30
Using Nanoplasmon-Enhanced Scattering and Low-Magnification Microscope Imaging to Quantify Tumor-Derived Exosomes
Published on: May 24, 2019
7.8K
Exosomes in early detection of urological Cancer
Maryam Rahnama1, Arezoo Mesri2, Navid Ghasemzadeh1
1Student Research Committee, Urmia University of Medical Sciences, Urmia, Iran.
Clinica Chimica Acta; International Journal of Clinical Chemistry
|November 6, 2025
Summary
Urinary exosomes show promise as non-invasive biomarkers for diagnosing urological cancers via liquid biopsy. Further standardization is crucial for their clinical integration in precision oncology.
Area of Science:
- Biochemistry
- Molecular Biology
- Oncology
Background:
- Exosomes, small extracellular vesicles, mediate intercellular communication by transferring biomolecules.
- They play roles in physiological and pathological processes, including modulating the tumor microenvironment (TME).
- Tumor-associated macrophages (TAMs) within the TME influence tumor progression.
Purpose of the Study:
- To review the significance of exosomes, particularly urinary exosomes (uEVs), as biomarkers for liquid biopsy.
- To highlight the role of uEVs in the diagnosis and management of urological cancers.
- To discuss challenges and future directions for clinical translation.
Main Methods:
- Literature review consolidating knowledge on exosomes and their role in urological cancers.
- Discussion of exosome composition and function in intercellular communication.
- Analysis of current challenges and technological advancements for uEV analysis.
Main Results:
- Exosomes carry functional proteins, metabolites, and nucleic acids, acting as critical mediators in the TME.
- Urinary exosomes (uEVs) offer a non-invasive diagnostic approach for urological cancers.
- Molecular contents of uEVs provide insights for early disease detection and monitoring.
Conclusions:
- Urinary exosomes are valuable biomarkers for non-invasive diagnosis and management of urological cancers.
- Standardization of protocols and addressing exosome heterogeneity are key for clinical translation.
- Advances in microfluidics, biosensors, and AI analytics can overcome current limitations, enabling integration into precision oncology.

